Full Text
REGD. No. D. L.-33004/99
The Gazette of India
CG-DL-E-27032025-262021
EXTRAORDINARY
PART II-Section 3-Sub-section (ii)
PUBLISHED BY AUTHORITY
No. 1457] NEW DELHI, THURSDAY, MARCH 27, 2025/CHAITRA 6, 1947
MINISTRY OF CHEMICALS AND FERTILIZERS
(Department of Pharmaceuticals)
(NATIONAL PHARMACEUTICAL PRICING AUTHORITY)
ORDER
New Delhi, the 27th March, 2025
S.O. 1475(E):— In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11,14 and 16 of
the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated 30th May, 2013, S.O. 1192(E) dated 22nd March,
2016 and S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals
and Fertilizers and in supersession of the order of the Government of India in the Ministry of Chemicals and
Fertilizers (National Pharmaceutical Pricing Authority) S.O. No. 1554(E) dated 26.3.2024 in so far as it relate to
formulation packs mentioned in the Table A below, manufactured by the manufacturers specified in Table B for
specified products and pack-sizes, except in respect of things done or omitted to be done before such supersession, the
National Pharmaceutical Pricing Authority, hereby revises the price based on Wholesale price index (WPI) of 2024 as
specified in column (5) of the Table A herein below as separate ceiling price exclusive of Goods and Services Tax
applicable, if any, in respect of the scheduled formulations specified in the corresponding entry in column (2) of the
said Table with the dosage form and strength and unit/packaging specified respectively in the corresponding entries in
columns (3) and (4) thereof:
Table A
Price Revision as per Annual Wholesale Price Index (WPI) @ 1.74028% increase.
+-----+-----------------------------------+-----------------------------------+---------------------------+-------------------------------------------------+
| Sl | Medicines | Dosage form and | Unit | Ceiling price (wef 1.4.2025 |
| No | | Strength | | with WPI @ 1.74028%) (in |
| | | | | Rs.) |
+=====+===================================+===================================+===========================+=================================================+
| (1) | (2) | (3) | (4) | (5) |
+-----+-----------------------------------+-----------------------------------+---------------------------+-------------------------------------------------+
| 1 | Piperacillin (A) + | Powder for | Per Dual chamber bag | 224.10 |
| | Tazobactam (B) | Injection 2 g (A) + | with special feature | |
| | | 250 mg(B) | | |
+-----+-----------------------------------+-----------------------------------+---------------------------+-------------------------------------------------+
| 2 | Piperacillin (A) + | Powder for | Per Dual chamber bag | 467.30 |
| | Tazobactam (B) | Injection 4 g (A) + | with special feature | |
| | | 500 mg(B) | | |
+-----+-----------------------------------+-----------------------------------+---------------------------+-------------------------------------------------+
TABLE 'B'
+--------+-----------------------------------+---------------------------+
| Sl. No. | Name of Manufacturer | Product/Brand Name |
+--------+-----------------------------------+---------------------------+
| (1) | (2) | (3) |
+--------+-----------------------------------+---------------------------+
| 1 | M/s Gufic Biosciences Limited | Tazofic Injection (DCB) |
+--------+-----------------------------------+---------------------------+
Note:
(a) The ceiling prices are applicable with effect from 1.4.2025 (ceiling prices are inclusive of Wholesale Price Index
(WPI) @ 1.74028% for the year 2024 over 2023).
(b) The manufacturers of scheduled formulations, selling above said products/brands of scheduled formulations at
price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the
Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified
in column (5) in the above table plus Goods and Services Tax as applicable, if any.
(c) The manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price notified
vide S.O. No. 1554(E) dated 26.3.2024 (plus Goods and Services Tax as applicable, if any), may revise the
existing M.R.P. of their formulations, on the basis of WPI @ 1.74028% for year 2024 over 2023 in accordance
with paragraph 16(2) of DPCO, 2013.
(d) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the
Government on the ceiling price mentioned in column (5) of the above said table.
(e) Any other manufacturer claiming separate ceiling price for Piperacillin (A) + Tazobactam (B) Injection (i)
Powder for injection 2g (A) + 250mg (B) (ii) 4g (A) + 500mg (B) Per Dual chamber bag having special features
shall apply to NPPA for separate ceiling price approval.
(f) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or
physical form in Form-II within a period of fifteen days of such revision and non-submission of information
under this sub-paragraph shall be construed as non revision of maximum retail price (MRP) and the concerned
manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail price
(MRP), alongwith interest thereon from the date of overcharging.
(g) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in
accordance with the ceiling price specified in column (5) of the above table as per provisions contained in
paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V
from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to
State Drug Controller and dealers.
(h) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price
list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business
in a manner so as to be easily accessible to any person wishing to consult the same.
(i) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the
above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall
apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the
DPCO, 2013.
(j) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of
production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through
IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall
furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled
formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of
discontinuation.
(k) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit
the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order,
2013 read with Essential Commodities Act, 1955.
(l) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in
this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of
notification, stand(s) superseded.
[PN/263/131/2025/F/F. No. 8(131)/2025/D.P./NPPA-Div.-II]
MAHAVEER SAINI, Dy. Director
Uploaded by Dte. of Printing at Government of India Press, Ring Road, Mayapuri, New Delhi-110064
and Published by the Controller of Publications, Delhi-110054.